MiNK Therapeutics (INKT) Non-Current Debt (2022 - 2024)

MiNK Therapeutics (INKT) posted Non-Current Debt of $4.9 million for Q4 2024, up 6.79% sequentially from $4.6 million in Q3 2024.

MiNK Therapeutics (INKT) Non-Current Debt (2022 - 2024) Analysis & Trends

MiNK Therapeutics has reported Non-Current Debt for 3 years, with the latest figure at $4.9 million in Q4 2024.

Quarterly Non-Current Debt changed N/A year-over-year to $4.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $4.9 million (changed N/A YoY) and the FY2024 annual result came in at $4.9 million, changed N/A from the prior year.
Non-Current Debt grew to $4.9 million in Q4 2024 per INKT's latest filing, from $4.6 million in the prior quarter.
Over five years, Non-Current Debt peaked at $9.7 million in Q1 2023 and troughed at $4.2 million in Q1 2024.
A 3-year average of $6.2 million and a median of $4.8 million in 2024 frame the typical range for Non-Current Debt.
The widest YoY moves for Non-Current Debt: up 56.67% in 2024, down 56.67% in 2024.
Over 3 years, Non-Current Debt stood at $9.1 million in 2022, then gained by 7.04% to $9.7 million in 2023, then plunged by 49.34% to $4.9 million in 2024.
According to Business Quant data, Non-Current Debt over the past three periods registered $4.9 million, $4.6 million, and $4.4 million for Q4 2024, Q3 2024, and Q2 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	8.96 Bn
10	MiNK Therapeutics	60.53 Mn	60.53 Mn	-	-

Download Data